Volume | 100,125 |
|
|||||
News | - | ||||||
Day High | 2.95 | Low High |
|||||
Day Low | 2.82 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Maia Biotechnology Inc | MAIA | AMEX | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.93 | 2.82 | 2.95 | 3.05 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
430 | 100,125 | $ 2.89 | $ 289,147 | - | 0.82 - 3.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:25:55 | 100 | $ 2.85 | USD |
Maia Biotechnology Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
40.51M | 14.21M | - | 0 | -19.77M | -1.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Maia Biotechnology News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MAIA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.36 | 3.40 | 2.7048 | 3.01 | 265,232 | -0.51 | -15.18% |
1 Month | 2.02 | 3.59 | 1.851 | 2.95 | 297,745 | 0.83 | 41.09% |
3 Months | 1.53 | 3.59 | 1.24 | 2.26 | 382,763 | 1.32 | 86.27% |
6 Months | 1.70 | 3.59 | 0.82 | 1.77 | 376,714 | 1.15 | 67.65% |
1 Year | 2.49 | 3.59 | 0.82 | 1.87 | 255,208 | 0.36 | 14.46% |
3 Years | 4.10 | 9.64 | 0.82 | 3.36 | 232,410 | -1.25 | -30.49% |
5 Years | 4.10 | 9.64 | 0.82 | 3.36 | 232,410 | -1.25 | -30.49% |
Maia Biotechnology Description
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells. |